MediciNova Shares Rise 14% After Positive Data for MN-166 Trial
By Chris Wack MediciNova shares were up 14% to $2.30 after the company reported positive data for its phase 2 clinical trial of MN-166 ibudilast in...
Chris Wack Article Normal Financial Performance Share Price Movement Disruptions New Products Services Research Development
Source: marketwatch.com